Review article · 2022 · Open access

PROTAC targeted protein degraders: the past is prologue

Miklós Békés, David R. Langley, Craig M. Crews

Nature Reviews Drug Discovery, 21(3), 181–200 · Published 18 January 2022 · DOI 10.1038/s41573-021-00371-6

Open PDFView at the publisherCite this paper

In brief

“PROTAC targeted protein degraders: the past is prologue” is a 2022 review article by Miklós Békés and 2 co-authors, published in Nature Reviews Drug Discovery. OpenAlex counts 3,712 citations as of 21 November 2026. It is open access: the full text is free to read at Nature Reviews Drug Discovery.

Citations
3,712
Most cited in
2026 (1,078)
Field-weighted impact
64.50
References
254
Authors
3

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Békés, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 21(3), 181–200. https://doi.org/10.1038/s41573-021-00371-6

MLA 9

Békés, Miklós, et al. “PROTAC targeted protein degraders: the past is prologue.” Nature Reviews Drug Discovery, vol. 21, no. 3, 2022, pp. 181–200. https://doi.org/10.1038/s41573-021-00371-6.

Chicago

Békés, Miklós, David R. Langley, and Craig M. Crews. 2022. “PROTAC targeted protein degraders: the past is prologue.” Nature Reviews Drug Discovery 21 (3): 181–200. https://doi.org/10.1038/s41573-021-00371-6.

Harvard

Békés, M., Langley, D. R. and Crews, C. M. (2022) ‘PROTAC targeted protein degraders: the past is prologue’, Nature Reviews Drug Discovery, 21(3), pp. 181–200. doi:10.1038/s41573-021-00371-6.

IEEE

M. Békés, D. R. Langley, and C. M. Crews, “PROTAC targeted protein degraders: the past is prologue,” Nature Reviews Drug Discovery, vol. 21, no. 3, pp. 181–200, 2022, doi: 10.1038/s41573-021-00371-6.

BibTeX

@article{bekes2022protac,
  title     = {{PROTAC targeted protein degraders: the past is prologue}},
  author    = {Békés, Miklós and Langley, David R. and Crews, Craig M.},
  journal   = {Nature Reviews Drug Discovery},
  year      = {2022},
  volume    = {21},
  number    = {3},
  pages     = {181--200},
  doi       = {10.1038/s41573-021-00371-6},
  url       = {https://doi.org/10.1038/s41573-021-00371-6}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201411
2022239239
2023561561
2024813813
20251,0191019
20261,0781078

Its field-weighted citation impact is 64.50: it has been cited 64.50 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • targeted protein degradation
  • ubiquitin-proteasome system
  • ubiquitin ligase
  • undruggable targets
  • cancer therapeutics
  • precision medicine
  • drug discovery

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Békés, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 21(3), 181–200. https://doi.org/10.1038/s41573-021-00371-6

How many times has this paper been cited?

3,712 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Reviews Drug Discovery: sign in and open the PDF from this page.

Who wrote this paper?

Miklós Békés, David R. Langley, Craig M. Crews.

What is the DOI of this paper?

10.1038/s41573-021-00371-6, permanently at https://doi.org/10.1038/s41573-021-00371-6. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.